| XLS |
|
|
|
|
|
€ million |
2011 |
2010 |
|
Profit after tax |
629.0 |
641.5 |
|
Available-for-sale financial assets |
|
|
|
Fair value adjustments |
26.5 |
–6.5 |
|
Reclassification to income statement |
–24.2 |
–17.1 |
|
Deferred taxes |
1.6 |
1.8 |
|
Changes recognized in equity |
3.9 |
–21.8 |
|
Derivative financial instruments |
|
|
|
Fair value adjustments |
–50.1 |
–125.3 |
|
Reclassification to income statement |
12.3 |
17.2 |
|
Reclassification to assets |
– |
–24.4 |
|
Deferred taxes |
4.3 |
23.9 |
|
Changes recognized in equity |
–33.5 |
–108.6 |
|
Actuarial gains and losses from defined benefit obligations and similar obligations |
|
|
|
Changes in actuarial gains and losses |
–27.7 |
–170.7 |
|
Deferred taxes |
7.4 |
28.5 |
|
Changes recognized in equity |
–20.3 |
–142.2 |
|
Exchange differences on translating foreign operations |
|
|
|
Change recognized in equity |
–47.9 |
840.5 |
|
Reclassification to income statement |
3.5 |
– |
|
Changes recognized in equity |
–44.4 |
840.5 |
|
Gains/losses recognized immediately in equity |
–94.3 |
567.9 |
|
Comprehensive income |
534.7 |
1,209.4 |
|
of which attributable to Merck KGaA shareholders |
527.1 |
1,194.4 |
|
of which attributable to non-controlling interest |
7.6 |
15.0 |